

HIV Cure Funding Opportunity Announcement

Through the Corporate Grants program, Gilead intends to support the efforts of academic institutions, non-profit organizations and community groups engaged in activities related to suppressing or eliminating HIV without antiretroviral therapy. Specifically, Gilead is looking to support the following four areas:

1. Translational Research

- Proof of concept and early translational research supporting novel therapeutic interventions aiming to reduce HIV reservoirs and/or enhance immune-mediated control of HIV.
- Development of assays that would be used to evaluate the HIV reservoir and assess the impact of therapeutic interventions.
- Explore the HIV reservoir and the impact of therapeutic interventions in acutely HIV-infected individuals.

2. Efficacy Studies in Animal Models

• Animal models of AIDS to test novel therapeutic concepts targeting the viral reservoir and/or enhancing immunemediated control of AIDS viruses.

3. Institutional Funding

• Institutional programs currently engaged in HIV cure research.

4. Community Groups

 Research among HIV-infected individuals and affected communities to understand potential concerns related to HIV cure clinical research.

Selection Criteria & Eligibility

Gilead encourages proposals from investigators that can demonstrate the following:

- Track record of excellence in results-driven research.
- Original, innovative ideas in multidisciplinary, collaborative research.
- Organizations must be classified as a not-for-profit organization or institution.

Key Dates & Program Specifics

- May 1, 2016: Letter of Intent submission deadline
- June 1, 2016: Disposition of formal Requests for Proposal
- Oct. 1, 2016: Full proposal submission deadline
- Nov. 15, 2016: Award notification announcement
- Completed letters of intent and questions about the announcement or LOI form should be submitted to grants@gilead.com.
- The program provides awards for up to a three-year period and up to \$2,500,000 per award. Award period and amounts will vary depending on grant category.
- Application to the Corporate Grants program is not a promise of funding.

Gilead reserves the right to approve or disapprove any application. Applications are reviewed by an internal Grants Review Committee. Award of a grant in any one cycle does not infer that a subsequent grant will be awarded without further application and approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.